These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 22056397

  • 1. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    JAMA; 2011 Dec 07; 306(21):2340-7. PubMed ID: 22056397
    [Abstract] [Full Text] [Related]

  • 2. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, Hoppenreijs EP, Armbrust W, Gorter SL, van Pelt PA, Kamphuis SS, Dolman KM, Swart JF, van den Berg JM, Koopman-Keemink Y, van Rossum MA, Wulffraat NM, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2015 Jul 07; 74(7):1379-86. PubMed ID: 24641940
    [Abstract] [Full Text] [Related]

  • 3. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2009 May 07; 68(5):635-41. PubMed ID: 18413443
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.
    Arthritis Rheum; 2003 Apr 07; 48(4):1093-101. PubMed ID: 12687553
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
    Otten MH, Prince FH, Anink J, Ten Cate R, Hoppenreijs EP, Armbrust W, Koopman-Keemink Y, van Pelt PA, Kamphuis S, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2013 May 07; 72(5):721-7. PubMed ID: 22730374
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H, German and Austrian Paediatric Rheumatology Collaborative Study Group.
    Ann Rheum Dis; 2009 Apr 07; 68(4):519-25. PubMed ID: 18413440
    [Abstract] [Full Text] [Related]

  • 8. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW.
    J Rheumatol; 2011 Oct 07; 38(10):2258-63. PubMed ID: 21844151
    [Abstract] [Full Text] [Related]

  • 9. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.
    Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR, Hull RG, Venning HE, Rahman JK, Cummins CL, British Society for Adolescent and Paediatric Rheumatology Biologics and New Drugs Register.
    Rheumatology (Oxford); 2011 Jan 07; 50(1):189-95. PubMed ID: 21047801
    [Abstract] [Full Text] [Related]

  • 10. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
    Anink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF, ten Cate R, van Rossum MA, van den Berg JM, Dolman KM, Koopman-Keemink Y, Armbrust W, Kamphuis S, van Pelt PA, Gorter SL, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2013 Apr 07; 52(4):712-7. PubMed ID: 23267169
    [Abstract] [Full Text] [Related]

  • 11. Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis.
    Haapasaari J, Kautiainen H, Hannula S, Pohjankoski H, Hakala M.
    Clin Exp Rheumatol; 2002 Apr 07; 20(6):867-70. PubMed ID: 12508784
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kümmerle-Deschner JB, Tenbrock K, Ganser G, Huppertz HI.
    Arthritis Rheumatol; 2015 May 07; 67(8):2240-9. PubMed ID: 25891010
    [Abstract] [Full Text] [Related]

  • 13. A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission.
    Pratsidou-Gertsi P, Trachana M, Pardalos G, Kanakoudi-Tsakalidou F.
    Clin Exp Rheumatol; 2010 May 07; 28(6):919-22. PubMed ID: 21205467
    [Abstract] [Full Text] [Related]

  • 14. Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register.
    Anink J, Prince FH, Dijkstra M, Otten MH, Twilt M, ten Cate R, Gorter SL, Koopman-Keemink Y, van Rossum MA, Hoppenreijs EP, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2015 Nov 07; 54(11):1964-9. PubMed ID: 26078219
    [Abstract] [Full Text] [Related]

  • 15. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
    Anink J, Otten MH, Gorter SL, Prince FH, van Rossum MA, van den Berg JM, van Pelt PA, Kamphuis S, Brinkman DM, Swen WA, Swart JF, Wulffraat NM, Dolman KM, Koopman-Keemink Y, Hoppenreijs EP, Armbrust W, ten Cate R, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2013 Sep 07; 52(9):1674-9. PubMed ID: 23740187
    [Abstract] [Full Text] [Related]

  • 16. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2009 Apr 07; 68(4):552-7. PubMed ID: 18467515
    [Abstract] [Full Text] [Related]

  • 17. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept.
    Solari N, Palmisani E, Consolaro A, Pistorio A, Viola S, Buoncompagni A, Gattorno M, Picco P, Ruperto N, Malattia C, Martini A, Ravelli A.
    J Rheumatol; 2013 Feb 07; 40(2):192-200. PubMed ID: 23204218
    [Abstract] [Full Text] [Related]

  • 18. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
    Aikawa NE, França IL, Ribeiro AC, Sallum AM, Bonfa E, Silva CA.
    Vaccine; 2015 Jan 29; 33(5):604-9. PubMed ID: 25554240
    [Abstract] [Full Text] [Related]

  • 19. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia.
    Alexeeva EI, Namazova-Baranova LS, Bzarova TM, Valieva SI, Denisova RV, Sleptsova TV, Isaeva KB, Chomahidze AM, Taibulatov NI, Fetisova AN, Karaseva AV, Baranov AA.
    Pediatr Rheumatol Online J; 2017 Jun 14; 15(1):51. PubMed ID: 28615036
    [Abstract] [Full Text] [Related]

  • 20. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis.
    Simonini G, Giani T, Stagi S, de Martino M, Falcini F.
    Rheumatology (Oxford); 2005 Jun 14; 44(6):777-80. PubMed ID: 15741191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.